The estimated Net Worth of Cuong V Do is at least $1.26 Million dollars as of 4 March 2024. Mr Do owns over 10,000 units of BioVie stock worth over $1,259,618 and over the last 15 years he sold BIVI stock worth over $0. In addition, he makes $0 as Pres und CEO & Director at BioVie.
Mr has made over 6 trades of the BioVie stock since 2010, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of BIVI stock worth $28,900 on 4 March 2024.
The largest trade he's ever made was exercising 41,506 units of BioVie stock on 21 June 2023 worth over $119,952. On average, Mr trades about 2,892 units every 167 days since 2009. As of 4 March 2024 he still owns at least 435,854 units of BioVie stock.
You can see the complete history of Mr Do stock trades at the bottom of the page.
Cuong Viet Do M.B.A., MBA is the Pres, CEO & Director at BioVie.
Mr MBA is 55, he's been the Pres und CEO & Director of BioVie since . There are 8 older and no younger executives at BioVie. The oldest executive at BioVie Inc. is Steven Gorlin, 82, who is the Director.
Cuong's mailing address filed with the SEC is C/O BIOVIE INC., 680 W NYE LANE STE 201, CARSON CITY, NV, 89703.
Over the last 9 years, insiders at BioVie have traded over $352,740 worth of BioVie stock and bought 67,100 units worth $464,015 . The most active insiders traders include Terren S Peizer, Steve Gorlin und Richard J Berman. On average, BioVie executives and independent directors trade stock every 122 days with the average trade being worth of $301,811. The most recent stock trade was executed by Cuong V Do on 4 March 2024, trading 10,000 units of BIVI stock currently worth $28,900.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.
BioVie executives and other stock owners filed with the SEC include: